Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Analysis of Outcomes Among Rheumatoid Arthritis Patients Treated With Xeljanz Versus Biologic DMARDs Using a United States Healthcare Claims Database

Next Previous
Trial Profile

Comparative Analysis of Outcomes Among Rheumatoid Arthritis Patients Treated With Xeljanz Versus Biologic DMARDs Using a United States Healthcare Claims Database

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 13 May 2020 Status changed from active, no longer recruiting to completed.
  • 18 Feb 2020 Planned End Date changed from 15 Dec 2019 to 15 Mar 2020.
  • 18 Feb 2020 Planned primary completion date changed from 15 Dec 2019 to 15 Mar 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top